Xeltis
Xeltis develops artificial vessels and valves that utilize Endogenous Tissue Restoration technology to be replaced by a patient's own living tissue. Its primary product, aXess, is a vascular access conduit for hemodialysis patients designed to reduce risks of thrombosis and infection. The company also targets applications in coronary arterial bypass surgery, pulmonary heart valves, and peripheral arterial disease.
Healthtech
Medical Devices
Biotechnology
Funding summary
- Total raised
- €160.9M
- Funding rounds
- 8
Investors in Xeltis
Investors on record for Xeltis. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Xeltis?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors